Merck has formed a broad collaboration with Idera Pharmaceuticals to research, develop and commercialize Idera’s Toll-like Receptor (TLR) agonists by incorporating them in therapeutic and prophylactic vaccines being developed by Merck for oncology, infectious diseases and Alzheimer’s disease. “Our collaboration with Idera is part of Merck’s long-standing commitment to research and develop novel vaccines and medicines that can improve human health,” said Peter S. ...